Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594
- 1 July 2013
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 81 (1) , 47-52
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancerBritish Journal of Cancer, 2011
- Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?Chemotherapy Research and Practice, 2010
- RETRACTED ARTICLE: Identification of thymidylate synthase as a potential therapeutic target for lung cancerBritish Journal of Cancer, 2010
- Significance of thymidylate synthase for resistance to pemetrexed in lung cancerCancer Science, 2009
- Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancerAnnals of Oncology, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- P2-328: Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)Journal of Thoracic Oncology, 2007
- Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthaseCancer, 2006
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003